Movement disorders clinical practice · 2025
Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kamo Hikaru, Oyama Genko, Shimizu Mai, Takeshige-Amano Haruka, Ogawa Takashi, Sako Wataru, Nishikawa Noriko, Hatano Taku, Li Yuanzhe, Yoshino Hiroyo, Funayama Manabu, Ito Masanobu, Iwamuro Hirokazu, Umemura Atsushi, Hattori Nobutaka
Аннотация
BACKGROUND: Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant-the causative gene of Gaucher disease-associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)-DBS.
OBJECTIVES: The aim of the study was to examine the relationship between outcomes after STN-DBS and GBA1 variants in PD patients undergoing bilateral STN-DBS.
METHODS: Patients were retrospectively analyzed over 5 years, with clinical and genetic assessments, including GBA1 variant status performed at baseline and at 1-, 3-, and 5-years post-DBS. Longitudinal changes in motor, cognitive, and medication outcomes were evaluated using propensity score matching and linear mixed-effects models.
RESULTS: A total of 371 PD patients undergoing bilateral STN-DBS were analyzed, including 54 GBA1 variant carriers and 253 noncarriers, after excluding other genetic variants. Propensity score matching yielded 2 groups with balanced baseline characteristics, with 50 patients each. Over time, no significant differences were observed in motor, cognitive, or neuropsychiatric assessments between groups. GBA1 carriers exhibited worsened medication OFF-DBS off state motor symptoms at 5 years postoperatively, whereas cognitive function, assessed by the Mini-Mental State Examination, remained stable in both groups. Levodopa-equivalent daily dose (LEDD) significantly decreased in both groups. Linear mixed-effects models showed progressive motor and cognitive decline and reduced medication use over 5 years, with no significant impact on GBA1 variant status.
CONCLUSIONS: Findings from Japan's largest genetic cohort suggest that GBA1 variants may not significantly affect postoperative motor or cognitive trajectories following STN-DBS. Further validation through large-scale multinational and multicenter studies is warranted.
OBJECTIVES: The aim of the study was to examine the relationship between outcomes after STN-DBS and GBA1 variants in PD patients undergoing bilateral STN-DBS.
METHODS: Patients were retrospectively analyzed over 5 years, with clinical and genetic assessments, including GBA1 variant status performed at baseline and at 1-, 3-, and 5-years post-DBS. Longitudinal changes in motor, cognitive, and medication outcomes were evaluated using propensity score matching and linear mixed-effects models.
RESULTS: A total of 371 PD patients undergoing bilateral STN-DBS were analyzed, including 54 GBA1 variant carriers and 253 noncarriers, after excluding other genetic variants. Propensity score matching yielded 2 groups with balanced baseline characteristics, with 50 patients each. Over time, no significant differences were observed in motor, cognitive, or neuropsychiatric assessments between groups. GBA1 carriers exhibited worsened medication OFF-DBS off state motor symptoms at 5 years postoperatively, whereas cognitive function, assessed by the Mini-Mental State Examination, remained stable in both groups. Levodopa-equivalent daily dose (LEDD) significantly decreased in both groups. Linear mixed-effects models showed progressive motor and cognitive decline and reduced medication use over 5 years, with no significant impact on GBA1 variant status.
CONCLUSIONS: Findings from Japan's largest genetic cohort suggest that GBA1 variants may not significantly affect postoperative motor or cognitive trajectories following STN-DBS. Further validation through large-scale multinational and multicenter studies is warranted.